At the news
? NEUTRALIMPACT 4/10 8-K filed Sep 14, 2026 at 08:00 ET
Cabaletta Bio reports that warrants issued in a June 2025 public offering expired on September 12, 2026, and that 97% (46.0M of 53.1M) were exercised in the three months before expiration, generating $115M in aggregate gross proceeds in Q3 2026 and ~$128.2M total since issuance. The filing is a routine update on warrant exercise activity and contains no new operational or pipeline developments.
- 53,090,190 common stock warrants were issued in June 2025 with a $2.50 exercise price and an expiration date of September 12, 2026.
- 5,275,100 warrants were exercised from issuance through June 30, 2026, generating ~$13.2M in gross proceeds.
- 46,011,900 warrants were exercised from July 1, 2026 through the expiration date, generating ~$115.0M in aggregate gross proceeds.
- Total aggregate gross proceeds from all warrant exercises: approximately $128.2 million.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access